Cellyan Biotechnology Income Statement

Financials in millions USD. Fiscal year is April - March.

Millions USD. Fiscal year is Apr - Mar.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023
Period Ending	Sep '25 Sep 30, 2025	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023
Revenue	16.36	20.31	16.69	12.56
Revenue Growth (YoY)	-21.23%	21.72%	32.91%	-
Cost of Revenue	14.92	17.9	13.13	9.82
Gross Profit	1.44	2.42	3.56	2.74
Selling, General & Admin	2.06	2.22	1.89	1.76
Other Operating Expenses	0	0.01	0	0
Operating Expenses	2.06	2.22	1.89	1.76
Operating Income	-0.62	0.19	1.67	0.98
Interest Expense	-0.11	-0.1	-0.08	-0.02
Interest & Investment Income	0	0	0	0
Currency Exchange Gain (Loss)	-0.02	-0.01	-0.06	-0.03
EBT Excluding Unusual Items	-0.75	0.09	1.52	0.92
Gain (Loss) on Sale of Investments	-0.01	-0.04	-	-
Gain (Loss) on Sale of Assets	-0.01	-0.01	0	-
Other Unusual Items	-	-	0	0.1
Pretax Income	-0.77	0.04	1.53	1.02
Income Tax Expense	-0.07	0.06	0.2	0.02
Net Income	-0.7	-0.03	1.33	1
Net Income to Common	-0.7	-0.03	1.33	1
Net Income Growth	-	-	33.21%	-
Shares Outstanding (Basic)	11	10	7	7
Shares Outstanding (Diluted)	11	10	7	7
Shares Change (YoY)	19.69%	38.56%	7.64%	-
EPS (Basic)	-0.07	-0.00	0.18	0.15
EPS (Diluted)	-0.07	-0.00	0.18	0.15
EPS Growth	-	-	23.76%	-
Free Cash Flow	-0.49	0.5	-0.45	1.61
Free Cash Flow Per Share	-0.05	0.05	-0.06	0.24
Gross Margin	8.80%	11.89%	21.32%	21.81%
Operating Margin	-3.81%	0.94%	10.00%	7.80%
Profit Margin	-4.29%	-0.13%	7.97%	7.95%
Free Cash Flow Margin	-3.01%	2.46%	-2.68%	12.84%
EBITDA	-0.53	0.27	1.73	1.05
EBITDA Margin	-3.27%	1.31%	10.38%	8.39%
D&A For EBITDA	0.09	0.08	0.06	0.07
EBIT	-0.62	0.19	1.67	0.98
EBIT Margin	-3.81%	0.94%	10.00%	7.80%
Effective Tax Rate	-	174.92%	12.86%	2.21%

Source: S&P Capital IQ. Standard template. Financial Sources.